About Biovalence Technologies
-
May 26, 2020
2011
Founding of company, Biovalence Sdn Bhd
-
May 26, 2020
2013
US patent granted for “Antimicrobial Fusion Compound And Uses Thereof” by Abu Bakar Awang et al. US Patent Publication No. 2013/0336955 A1.
-
May 26, 2020
2014
Publication of Discovery Paper in PLOS ONE demonstrating the proof of concept of Biovalence Technologies recombinant proteomics technology against all 4 serotypes of the Dengue virus (Flaviviridae)
-
May 26, 2020
2014
Finalist at BioPharma 2014 showcasing the broad-spectrum antiviral activity of the world’s first genetically-designed antiviral proteins
-
May 26, 2020
2016
One of 4 recipients awarded for the Dengue Tech Challenge 2016 by the University of Cambridge, UK: https://www.britishcouncil.my/programmes/newton-ungku-omar-fund/dengue-tech-challenge-2016
-
May 26, 2020
Apr 2017
Finalist at BioPharma 2017 showcasing the pre-clinical studies of RetroMAD1, one of the 4 genetically-designed antiviral proteins
-
May 26, 2020
Aug 2017
Acquired by Singaporean angel investors and establishment of a Corporate HQs, Biovalence Technologies Pte Ltd, in Singapore for the purpose of attracting investors and commercialisation of RetroMAD1
-
May 26, 2020
Dec 2019
Publication of landmark field trial on RetroMAD1 in the treatment of feline leukaemia (Retroviridae) by the Federal University of Rio de Janeiro, Brazil
-
May 26, 2020
Mar 2020
The company is in the news with its commentary on the possible application of RetroMAD1 for Covid-19: https://www.scmp.com/news/asia/southeast-asia/article/3075604/coronavirus-singapore-start-thinks-cat-leukaemia-drug
-
May 26, 2020
Apr 2020
Pre-series A investment valuing the company at US$ 20 million
-
May 26, 2020
Apr 2020
Launch of e-commerce website, www.retromad1.com, for the US$16 billion pet therapeutics market
Management Team


Cher Yew NG
Chairman and
Chief Executive Officer


Awang MUHAMMAD
Chief Scientific Officer and
Chief Quality Assurance


Alfred CHUA
Chief Marketing Officer and
Chief Veterinary Officer


Ashley SIM
Chief Financial Officer and
Chief Information Officer